MaxiVAX SA is a clinical stage (Phase II) biotech company dedicated to the cure of cancer by immuno-therapy. Its treatment is capable of stimulating the natural immune response of the patient to eliminate cancer cells. Phase I clinical trials were completed with no safety issue, were well tolerated and with encouraging efficacy data. The company received the 2017 CTI Swiss Medtech Award for its ground-breaking work, and its lead product, MVX-ONCO-1, which is in Phase 2 development for Head & Neck cancer in Switzerland. The company successfully filed an IND with the US FDA in 2018.